ACADIA Pharmaceuticals Inc. EV/EBITDA

EV/EBITDA of ACAD for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/EBITDA growth rates and interactive chart. EV/EBITDA is a ratio that compares a company’s Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation & Amortization (EBITDA). The EV/EBITDA ratio is a valuation metric used to compare the relative value of different businesses. A low EV/EBITDA compared to a stock’s historical average or industry can indicate undervaluation.


Highlights and Quick Summary

Current EV/EBITDA of ACADIA Pharmaceuticals Inc. is 0.0 (as of December 30, 2020)
  • EV/EBITDA for the quarter ending March 30, 2021 was 0.0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly EV/EBITDA decreased by NaN%
  • Annual EV/EBITDA for 2020 was 0.0 (a NaN% decrease from previous year)
  • Annual EV/EBITDA for 2019 was 0.0 (a NaN% decrease from previous year)
  • Annual EV/EBITDA for 2018 was 0.0 (a NaN% decrease from previous year)
Visit stockrow.com/ACAD for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/EBITDA of ACADIA Pharmaceuticals Inc.

Most recent EV/EBITDAof ACAD including historical data for past 10 years.

Interactive Chart of EV/EBITDA of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. EV/EBITDA for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0
2020 0.0 0.0 0.0 0.0 0.0
2019 0.0 0.0 0.0 0.0 0.0
2018 0.0 0.0 0.0 0.0 0.0
2017 0.0 0.0 0.0 0.0 0.0
2016 0.0 0.0 0.0 0.0 0.0
2015 0.0 0.0 0.0 0.0 0.0
2014 0.0 0.0 0.0 0.0 0.0
2013 0.0 0.0 0.0 0.0 0.0
2012 0.0 0.0 0.0 0.0 0.0
2011 0.0 1.72 3.49 2.34 0.0
2010 0.0 0.0 0.0 0.0

Business Profile of ACADIA Pharmaceuticals Inc.

Sector: Healthcare
Industry: Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; Trofinetide, a novel synthetic analog for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor for treating cognition and schizophrenia. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.